Neurofilament light protein in plasma may be a noninvasive biomarker for neurodegeneration associated with Alzheimer's disease.
Researchers have devised a new blood test that can detect if amyloid had begun to accumulate in the brain. The test help physicians diagnose Alzheimer's disease in a cheaper, less invasive way than currently available. The researchers will present their findings at the Alzheimer's Association International Conference in London.
Researchers identified 33 metabolic compounds in blood samples that differed between those with dementia and cognitively healthy older adults. 7 of the metabolites were elevated in dementia patients, while 26 were at lower levels compared to samples of those without dementia. Elevating levels of those metabolites could have a neuroprotective effect against dementia.
A new method of examining blood plasma allowed researchers to identify specific chemical bonds within the blood. The new technique allowed researchers to accurately distinguish between Alzheimer's disease and Lewy body dementia, thus reducing cases of misdiagnosis.
Researchers have developed a blood test that looks at genetic markers to detect which babies who were deprived of oxygen at birth are at risk of developing neurodevelopment problems.
A newly developed blood test is 96% accurate in the early detection of Alzheimer's disease.
A new blood test to detect biomarkers for Alzheimer's disease is set to undergo trials in the Fall. The test will be able to identify traces of amyloid beta in blood samples with a high degree of accuracy.
Researchers use a simple blood test to detect evidence of concussion in patients up to 7 days after injury has occurred.
A new blood test for Alzheimer's disease is up-to 94% accurate at predicting dementia before symptoms appear. The test's accuracy is increased when genetic predisposition and age are taken into account. The new test may eventually replace PET neuroimaging, currently considered the gold standard, for early detection of Alzheimer's.
Researchers report they are nearing development of a blood test that will accurately detect Alzheimer's disease and give doctors the ability to intervene at the earliest stage of the disease.
Artificial IntelligenceDeep LearningFeaturedMachine LearningNeuroscienceOpen Neuroscience ArticlesPsychology··5 min read
Blood tests revealed specific epigenetic biomarkers for schizophrenia. Researchers applied machine learning to analyze the CoRSIVs region of the human genome to identify the schizophrenia biomarkers. Testing the model with an independent data set revealed the AI technology can detect schizophrenia with 80% accuracy.